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SUMMARY 
Gastrokine1 (GKN1) is a stomach-specific protein important for 
maintaining the physiological function of the gastric mucosa. GKN1 is 
down-regulated in gastric tumor tissues and derived cell lines so it has 
recently emerged as a potential biomarker for gastric cancer. The protein 
is characterized by the presence of a BRICHOS domain consisting of 
about 100 amino acids found in several unrelated proteins associated with 
major human diseases like BRI2, related to familial British and Danish 
dementia; Chondromodulin-I (ChM-I), linked to chondrosarcoma; Lung 
Surfactant Protein C (SP-C), associated with respiratory distress 
syndrome. Literature data show that recombinant BRICHOS domains 
from BRI2 and SP-C precursor (proSP-C) prevent fibrils formation of 
amyloid-beta peptide (Aβ) that is the major component of extracellular 
amyloid deposits in Alzheimer's disease. Aβ derives from the partial 
hydrolysis of the amyloid precursor protein (APP) catalyzed by β-and γ-
secretase. The hydrolysis produces amyloid peptides of 40 (about 90%) or 
42 (about 10%) amino acid residues. 
Main target of this thesis is to investigate the interaction between 
recombinant human GKN1 (rhGKN1) and Aβ(1-40) to explore whether 
also GKN1 was endowed by a chaperone activity toward amyloidogenic 
peptides. To this aim, Aβ was incubated in presence or absence of 
rhGKN1 and chicken cystatin, as negative control, at 10:1 molar ratios. 
Samples were then analyzed by SDS-PAGE. The aggregation of Aβ was 
also evaluated using Thioflavine T binding assay. Mass spectrometry and 
size-exclusion chromatography analysis were performed to characterize 
the interaction. The data obtained showed that rhGKN1 prevented 
amyloid aggregation and fibrils formation by inhibiting Aβ(1-40) 
polymerization. Surface plasmon resonance analysis of rhGKN1/Aβ 
interaction led to calculate a dissociation constant (KD) of 34 µM. These 
preliminary data strongly indicated that rhGKN1 possess anti-amyloid 
activity thus, it might play a role of molecular chaperone directed against 
unfolded segments with an ability to recognize amyloidogenic 
polypeptides and prevent their aggregation. 
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Regarding the mechanism by which GKN1 gene is inactivated in 
gastric cancer, this remains still unknown; so the second part of my work 
is focused to clarify the causes of GKN1 gene silencing and to determine 
if epigenetic mechanisms, such as histonic modifications, could also 
contribute to its down-regulation. To this aim, chromatin 
immunoprecipitation assays (ChIP) for H3K9triMe and its specific HMT 
SUV39H1 were performed on different samples from biopsies of normal 
and tumor human gastric tissue. The results showed that GKN1 down-
regulation in gastric cancer tissues is associated with high levels of 
H3K9triMe and with the recruitment of SUV39H1 on GKN1 promoter, 
suggesting the presence of an epigenetic transcriptional complex that 
negatively regulates GKN1 expression in gastric tumor. 
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RIASSUNTO 
La Gastrochina1 (GKN1) è una proteina stomaco-specifica importante per 
il mantenimento della funzione fisiologica della mucosa gastrica. La 
GKN1 è down-regolata nei tessuti tumorali gastrici e linee cellulari 
derivate, per cui è recentemente emersa come potenziale marcatore per il 
cancro gastrico. La proteina è caratterizzata dalla presenza di un dominio 
BRICHOS costituito da circa 100 amminoacidi e trovato in diverse 
proteine, non correlate tra loro, associate alle principali patologie umane 
come BRI2, coinvolta nella demenza familiare britannica e danese; la 
Condromodulina-I (ChM-I), collegata al condrosarcoma;  la Proteina C 
del Surfattante Polmonare (SP-C) associata alla sindrome da distress 
respiratorio. Dati di letteratura mostrano che il dominio BRICHOS 
ricombinante di BRI2 e del precursore della SP-C (proSP-C) previene la 
formazione delle fibrille del peptide beta-amiloide (Aβ) che è il maggiore 
componente dei depositi amiloidi extracellulari nel morbo di Alzheimer. 
Aβ deriva dall’idrolisi parziale della proteina precursore dell’amiloide 
(APP) catalizzata dalle β-e γ-secretasi. L’idrolisi produce peptidi amiloidi 
di 40 (circa il 90%) o 42 (circa il 10%) residui amminoacidici. 
Obiettivo principale di questa tesi è quello di indagare l’interazione 
tra la GKN1 umana ricombinante (rhGKN1) ed Aβ(1-40) per valutare se 
anche la GKN1 sia dotata di un’attività da chaperone mirata contro 
peptidi amiloidogenici. A questo scopo, Aβ è stato incubato in presenza 
ed assenza di rhGKN1 e cistatina di pollo, usata come controllo negativo, 
in un rapporto molare di 10:1. I campioni sono stati poi analizzati su 
SDS-PAGE. L’aggregazione di Aβ è stata valutata anche attraverso il 
saggio di legame alla Tioflavina T. Per caratterizzare l’interazione sono 
state effettuate analisi di spettrometria di massa e di cromatografia ad 
esclusione di massa. I dati ottenuti hanno mostrato che rhGKN1 previene 
l’aggregazione dell’amiloide e la formazione delle fibrille inibendo la 
polimerizzazione di Aβ(1-40). Analisi dell’interazione rhGKN1/Aβ 
svolte mediante risonanza plasmonica di superficie hanno permesso di 
calcolare una costante di dissociazione (KD ) DI 34 µM. Questi risultati 
preliminary indicano fortemente che rhGKN1 possiede un’attività anti-
amiloide per cui, potrebbe svolgere un ruolo di chaperone molecolare 
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diretto contro segmenti non correttamente ripiegati, con l’abilità di 
riconoscere polipeptidi amiloidogenici e prevenirne l’aggregazione. 
Resta ancora da chiarire il meccanismo attraverso il quale il gene 
della GKN1 viene inattivato nel cancro gastrico. La seconda parte del mio 
lavoro è stata volta a chiarire le cause del silenziamento del gene della 
GKN1 e a determinare se ci siano anche meccanismi epigenetici, come le 
modifiche istoniche, a contribuire alla sua down-regulation. A tale scopo 
sono stati effettuati saggi di immunoprecipitazione della cromatina (ChIP) 
su differenti campioni derivanti da biopsie di tessuto umano gastrico 
normale e tumorale, immunoprecipitando per la modifica istonica 
H3K9triMe e per la sua HMT specifica SUV39H1. I risultati hanno 
mostrato che il decremento della GKN1 in tessuti tumorali gastrici è 
associato ad alti livelli di H3K9triMe ed al reclutamento di SUV39H1 sul 
promotore della GKN1, suggerendo l’intervento di un complesso 
trascrizionale epigenetico a regolare negativamente l’espressione della 
GKN1 nel cancro gastrico. 
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INTRODUCTION 
 
1.1 Gastrokine 1 
Gastrokine1 protein, previously known as 18 kDa antrum mucosal protein 
(AMP-18) was subsequently called by the "Human Gene Nomenclature 
Committee" GKN1 for its tissue-specific expression and its highly 
conserved presence in the gastric mucosa of many mammals species (1, 
2). The gene coding for GKN1 (CA11) (accession number: BK0017373), 
is located in a 6 kb region of the chromosome 2p13 and contains 6 exons. 
Sequence analysis of the gene showed that the human transcript contains 
two potential translation start sites (ATG). The first start codon would 
generate a protein of 199 amino acids whereas the second ATG, located 
42 bp downstream, would make a protein of 185 amino acids. Among the 
two starting sites, the second appears more possible since it contains a 
Kozak sequence (GCAGCCAACATG). Comparison of the translated 
amino acid sequence of human GKN1 with that of other species showed 
homology only after the second ATG, and its product is predicted to be of 
18 kDa. In addition, amino acid sequencing of native GKN1 from pig and 
N-terminal Edman’s degradation of native human GKN1 confirmed that 
the protein was made of 185 amino acids containing a 20 amino acid 
extracellular signal peptide localized in the N-terminal region (Fig. 1) (1). 
The human protein is expressed in the stomach of healthy individuals but 
is absent in gastric adenocarcinoma tissues (1-3).  Moreover, our research 
team observed that the protein is down-regulated in samples from H. 
pylori infected gastric mucosa that is considered as one of the leading 
cause for gastric cancer development (4, 5). The biological function of 
GKN1 is currently unknown, some findings indicate that the protein is 
involved in the replenishment of the surface lumen epithelial cell layer, in 
maintaining mucosal integrity and could play a role in cell proliferation 
and differentiation (6, 7). After injury of the gastric mucosa, restoration 
may occur very rapidly in the presence of GKN1 (6). In contrast, if the 
protein is down regulated, the repair process may be hampered. In fact, 
application of GKN1 to gastrointestinal cells promoted epithelial 
restoration, probably the protein may exert its protective effect by 
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increasing accumulation of specific tight and adherens junction proteins 
and also protecting their loss after injury (8, 9). We also has been 
studying the effect of GKN1 on gastric cancer cell lines (AGS and 
MKN28). We found that overexpression of GKN1 in these cell lines 
stimulated the expression of Fas receptor. Moreover, compared to control 
cells, a significant increase of apoptosis, evaluated by TUNEL, was 
observed when GKN1 transfected cells were treated with a monoclonal 
antibody (IgM) anti-Fas. The activation of Fas expression was also 
observed by the overexpression of GKN1 in other cancer cell lines (10). 
In addition, in order to characterize the structural and functional 
properties of this protein, we produced a recombinant human GKN1 
(rhGKN1) and we tested it on normal and tumor cells trought a MTT 
assay which showed that the protein reduced cell proliferation of gastric 
cancer cells (AGS) compared to human embryonic kidney cells (HEK 
293) and non-gastric cancer cells (H1355) (11). These data suggest that 
GKN1 was able to exert its function as modulator of apoptotic signals 
specifically in gastric cancer suggesting a possible role of the protein as 
tumor suppressor, moreover GKN1 may play also an important role as 
biomarker in carcinogenic process. In fact, it was seen that individuals 
with a lower expression of the protein have an increased risk to develop 
gastric diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. GKN1 genomic location and GKN1 human transcript.  (Upper panel) 
Chromosome bands according to Ensembl and genomic location according to GeneLoc. 
(Lower panel) GKN1 protein structural prediction (12). 
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1.2 GKN1 and amyloidogenic property of BRICHOS domain 
GKN1 contains a conserved central structural BRICHOS domain of about 
100 amino acids containing two conservative cysteine residues most 
likely involved in disulfide bridges (Fig. 2). The BRICHOS domain has 
been found in proteins with a wide range of functions and disease 
associations and, in particular, the acronym “BRICHOS” refers to three 
proteins in which the domain was observed originally: BRI2, which is 
expressed in neurons and related to familial British and Danish dementia 
(FBD and FDD); Chondromodulin-I (ChM-I), a cartilage-specific 
glycoprotein related to chondrosarcoma and Lung Surfactant Protein C 
(SP-C), related to respiratory distress syndrome (RDS) (12). The putative 
association of GKN1 with such domain structure, and with at least three 
different possible functions, has been proposed, but not yet been 
conclusively demonstrated. Recent insights indicate that the tumor 
suppressor role of GKN1 might be ascribed to the presence of the 
BRICHOS domain. In fact, it has been found that the NH2-terminal 
hydrophobic region (signal peptide) and BRICHOS domain of GKN1 
were shown to suppress gastric cancer cell growth and recapitulate 
protein functions. The paper showed that the hydrophobic region and 
BRICHOS domain had a synergistic anti-cancer effect with 5-FU on 
tumor cell growth in contrast to what observed for mutants as control, 
implying that the NH2-terminal region and BRICHOS domain of GKN1 
are sufficient for tumor suppression (13). 
Although GKN1 seems to play an important role in gastric mucosa 
and in carcinogenic process, a full characterization of its structural and 
biological activities is still lacking. To accomplish this deficiency, we 
have recently reported the characterization and secondary structural 
properties of recombinant human GKN1 (rhGKN1) (11). Using bio-
informatics tools, we found that GKN1 BRICHOS domain showed 
structural features similar to those endowed by BRICHOS domain 
containing protein family. In particular, GKN1 3D model showed that its 
BRICHOS domain displayed a structural organization resembling that of 
the corresponding BRICHOS domain of Surfactant Protein C precursor 
(proSP-C), a transmembrane (TM) protein expressed in epithelial type II 
cells that contains a discordant helix forming the TM region. The proSP-
Introduction 
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C α-helix can misfold and form amyloid fibrils associated with 
pulmonary disease. It has also been shown that the C-terminal domain 
(CTC) of proSP-C and its BRICHOS domain protects the TM part of the 
protein from aggregation into amyloid. 
Recent literature data show that recombinant BRICHOS domains 
from BRI2 and proSP-C prevent fibrils formation of amyloid-beta peptide 
(Aβ) that is the major component of extracellular amyloid deposits in 
Alzheimer's disease (14-16). The Aβ peptide originates from the 
amyloidogenic processing of the amyloid precursor protein (APP), a type 
I ubiquitary membrane protein that undergoes a first cleavage by β-
secretase to liberate the soluble APP domain (sAPP) in the extracellular 
space, and the membrane bound APP-C99 fragment (CTF). Then, APP-
C99 is processed by the intramembrane aspartyl-protease gamma-
secretase (γ-secretase) composed of four subunits (presenilin, nicastrin, 
anterior pharynx-defective protein 1 and presenilin enhancer 2) to release 
Aβ peptides (40 or 42 residues) in the lumen, and the APP intracellular 
domain (AICD) in the cytosol. Alternatively, APP can undergo the non-
amyloidogenic processing, in which it is first cleaved by α-secretase to 
generate the sAPPα domain and the APP-C83 fragment (CTF). The latter 
is further cleaved by γ-secretase into the nontoxic p3 peptide and the 
AICD.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Amino acid sequences alignment of GKN1, proSP-C and BRI2 BRICHOS 
domain. The alignment was made with ClustaW. Asterisks and double dots mark 
identical residues and conservative replacements, respectively. 
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1.3 Gene-environment interaction in gastric cancer: epigenetics and 
GKN1 
Gastric cancer is a very complex and heterogeneous disease, and although 
much has been learned about the different genetic changes that eventually 
lead to its development, the detailed mechanisms still remain unclear. 
Malignant transformation of gastric cells is the consequence of a 
multistep process involving different genetic and epigenetic changes in 
numerous genes in combination with host genetic background and 
environmental factors. 
Epigenetics refers to a number of modifications in the chromatin 
structure that affect gene expression without altering the primary DNA 
sequence, and these changes lead to transcriptional activation or silencing 
of the gene. Recent evidences indicate that epigenetic modifications play 
a central role in gastric carcinogenesis and novel therapeutic approaches 
that target DNA methylation and histone modifications have emerged. A 
greater understanding of epigenetics and the therapeutic potential of 
intervention into these processes is necessary to help gastric cancer 
treatment (17). At present, the major components of epigenetic regulatory 
network include DNA methylation, histone modifications and non-coding 
RNAs, mainly microRNAs. DNA methylation is introduced by addition 
of a methyl group to the fifth carbon of a cytosine pyrimidine ring of 
DNA, which typically occurs in a CpG dinucleotide. In normal cells, 
approximately 80% of all CpGs are methylated. DNA of cancer cells is 
generally hypomethylated, while promoters of certain genes are 
hypermethylated, both of which are implicated in carcinogenesis. 
Promoter-specific increased methylation leads to silencing of the affected 
genes that may function as tumor suppressors and result in heritable 
transcriptional silence. Aging and chronic inflammation can induce 
methylation in CpG islands. Recent studies have described a number of 
genes that are silenced by hypermethylation in gastric cancer association 
with H. pylori or EBV infection including: cell growth-related genes 
p16(INK4a), p14(ARF) and APC; DNA-repair genes, hMLH1, BRCA1 
and MGMT; the cell adherence gene E-cadherin; as well as LOX, FLNC, 
HRASLS, HAND1, THBD and p41ARC. 
Recent advances underscore the importance of histone 
Introduction 
6 
 
modifications in the pathogenesis of gastric cancer. Histones are the basic 
unit of the nucleosome, consisting of two copies of each of the core 
histones, H2A, H2B, H3 and H4. H3 and H4 histones have long tails 
protruding from nucleosome that can be covalently modified. This allows 
regulatory proteins to access DNA and regulate transcription. 
Modifications of histone tails include methylation, acetylation, 
phosphorylation, ubiquitination, SUMOylation, citrullination and ADP-
ribosylation. The acetylation and deacetylation of key lysine residues of 
histone H3 and H4 are controlled by histone acetyltransferases and 
histone deacetylases (HDACs). Transcription becomes active when 
histones are acetylated by histone acetyltransferases (HAT), silenced 
when histones are deacetylated and silenced or activated when methylated 
by histone methyltransferases (HMT). Both histone H3 lysine K9 and 
H3K27 trimethylation are associated with gene silencing, while histone 
H3 lysine 4 is associated with active genes (18). Recent studies identified 
candidate genes with significant differences in H3K27triMe in gastric 
cancer samples compared to adjacent non-neoplastic gastric tissues. These 
genes included oncogenes, tumor suppressor genes, cell cycle regulators, 
and genes involved in cell adhesion. Moreover, higher levels of 
H3K27triMe produce gene expression changes in MMP15, UNC5B, and 
SHH. LAMB3 and LAMC2 gene are overexpressed in gastric cancer 
samples in comparison with non-neoplastic adjacent tissue samples. 
Overexpression of these genes is a result of the enrichment of 
H3K4TtriMe in the gene promoter. Park et al. showed that higher levels 
of global H3K9triMe, which is a repressive mark, was associated with 
higher T stage, lymphovascular invasion, and recurrence in gastric 
tumors. They also observed that the level of H3K9triMe was correlated 
with patient survival, because stronger methylation corresponded to a 
worse prognosis and intermediate methylation to an intermediate 
prognosis. These results have suggested that histone methylation results 
in a worse prognosis by inactivating certain tumor suppressor genes. 
Moreover, Li et al. used gastric cancer cell lines to demonstrate that the 
PRC1 member CBX7 initiated trimethylation of H3K9 at the p16 locus 
through recruitment and/or activation of the HMT SUV39H1 to the target 
locus. This finding links two repressive epigenetic landmarks, H3K9triMe 
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formation and PRC1 binding within the silenced domains in euchromatin, 
and builds up a full pathway for epigenetic inactivation of p16 by histone 
modifications. Histone hypoacetylation of the HLTF gene are linked to its 
reduced expression in gastric cancer. HLTF is a homolog to the SWI/SNF 
genes, which encode chromatin-remodeling enzymes and serves as a 
tumor suppressor. Histone H3 in the p21(WAF1/CIP1) promoter is 
hypoacetylated in gastric cancer; this hypoacetylation is associated with 
reduced p21(WAF1/CIP1) expression in gastric cancer specimens. 
Aberrant histone deacetylation are also linked to the silencing of the 
SLC5A8 gene in gastric cancer. SLC5A8 (solute carrier family 5, 
member 8) is a sodium co-transporter and a putative tumor suppressor 
(19). 
The mechanism by which GKN1 gene is silenced in gastric cancer 
and if epigenetic changes could also contribute to silencing GKN1 gene 
remains still unknown. Recently, Hwan Yoon et al. investigated this 
aspect in a sample group of 81 gastric carcinomas and 40 gastric 
adenomas: no mutation was detected in gastric tumors, hyper-methylation 
of GKN1 gene promoter was found only in two tumors, while DNA copy 
number and mRNA levels of GKN1 were significantly decreased in all 
gastric cancer samples (20). Another paper investigated Epstein-Barr 
Nuclear Antigen 1 (EBNA1) binding and epigenetic regulation of GKN1 
in gastric carcinoma cells: Epstein-Barr Virus (EBV) latently infects 
~10% of gastric carcinomas (GC). Epstein-Barr Nuclear Antigen 1 
(EBNA1) is expressed in EBV-associated GC, and can bind host DNA, 
where it may impact cellular gene regulation. The authors have been 
shown that EBNA1 binds directly to DNA upstream of GKN1 gene. They 
generated AGS-EBV, and AGS-EBNA1 cell lines to study the effects of 
EBNA1 on GKN1 mRNA expression with or without 5' azacytidine 
treatment. Results shown that GKN1 is transcriptionally silenced by DNA 
methylation and latent EBV infection further reduces GKN1 expression in 
AGS gastric carcinoma cells, and that siRNA depletion of EBNA1 
partially alleviates this repression. However, ectopic expression of 
EBNA1 slightly increased GKN1 and GKN2 basal mRNA levels, but 
reduced their responsiveness to demethylating agent. These findings 
demonstrate that EBNA1 binds to the divergent promoter of the GKN1 
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gene in gastric cancer cells, and suggest that EBNA1 contributes to the 
transcriptional complex and epigenetic deregulation of the GKN1 tumor 
suppressor gene in EBV positive gastric cancer (21). In conclusion, these 
studies indicate that epigenetic modifications could be involved in the 
deregulation of GKN1 gene in gastric cancer. However, in literature there 
are not yet investigations for histone modifications and for the 
recruitment of histone-modifier enzymes and co-repressors on GKN1 
gene in gastric cancer. Under this aspect, it would be important to clarify 
the epigenetic causes of GKN1 gene silencing associated to gastric cancer 
and to determine whether this event might be involved in the development 
and progression of gastric cancer. Additional functional and translational 
studies of GKN1 will broaden our understanding of the pathogenesis of 
gastric cancer, and provide us with novel diagnostic and therapeutic 
modalities for the disease. 
 
1.4 Scientific hypothesis and aim of the work 
On the basis of this data and in order to better understand the functional 
role of GKN1, the main target of this thesis was to explore whether also 
GKN1 was endowed by a chaperone-like activity toward amyloidogenic 
peptides. To this aim it was analyzed using biochemical, spectroscopic 
and mass spectrometry investigations how rhGKN1 interacts with and 
prevents fibril formation of Aβ(1-40), derived from the TM part of its 
precursor protein APP. 
The second part of the work aimed to clarify the causes of GKN1 
gene inactivation and to determine if the epigenetic mechanism of histone 
modifications could also contribute to regulate the gene expression. 
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MATERIALS AND METHODS  
 
2.1 Materials 
Amyloid β-peptide (1-40) (DAEFRHDSGYEVHHQKLVFFAEDVGS 
NKGAIIGLMVGGVV) was purchased from Abnova and stored as 
lyophilized powder at -80 °C until its use. To obtain monomeric starting 
solutions, the peptide was dissolved in dimethyl sulfoxide (DMSO) 
(Merck) at a concentration of 138.5 μM before being diluted in 
experimental buffer. Chicken cystatin was purchased from Sigma-Aldrich 
and dissolved at a concentration of 76.8 μM before being diluted in 
experimental buffer.  
 
2.2 GKN1 expression and Purification 
Recombinant human GKN1 (rhGKN1) was expressed and purified as 
described previously (11). Stock solutions with concentration of 313.3 
μM were used for the experiments. 
 
2.3 Aβ(1-40) aggregation and fibrils formation 
Aβ(1-40) was dissolved in DMSO at a concentration of 138.5 μM. 
Experiments were performed by co-incubating Aβ(1-40) (17.3 μM) with 
rhGKN1 (1.7 μM) at 37 °C in 10 mM sodium phosphate buffer (NaP) pH 
7.0 and 150 mM sodium chloride (NaCl) containing 10% (v/v) DMSO 
under agitation. At various time points, samples were removed to 
determine the level of aggregation. The samples were centrifuged for 6 
minutes at 14000 rpm and the supernatants were removed and centrifuged 
for an additional 2 minutes at the same speed. The supernatant from the 
last centrifugation was then analyzed by SDS-PAGE on 16% Tris-Tricine 
gels under nonreducing conditions and stained with Coomassie. As 
control, Aβ(1-40) was incubated with 1.7 μM chicken cystatin in the same 
manner as described above (22). 
 
2.4 Thioflavin T assay for Aβ(1-40) aggregation 
Thioflavin T binding was assessed on Aβ(1-40) incubated in the presence 
or absence of rhGKN1 at 5:1 molar ratio in 10 mM NaP pH 7.0 and 150 
mM NaCL 10% (v/v) DMSO at 37 °C under agitation. At various time 
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points, 100 μL aliquots were removed and 160 μL of Thioflavin T 50 μM 
were added in 10 mM NaP pH 7.0 and 150 mM NaCl. A sample with 
rhGKN1 alone was also included. The samples were incubated for 5 
minutes in the dark before fluorescence was measured. The wavelengths 
for excitation and emission were 450 and 482 nm, respectively. Each 
sample was measured in duplicate. 
 
2.5 MALDI-TOF mass spectrometry 
MALDI-MS experiments were performed in positive linear reflectron 
mode on a MALDI-TOF micro MX (Waters Co.), equipped with a pulsed 
nitrogen laser (λ=337 nm). The instrument was calibrated using a three-
point external calibration using a mixture (10 pmol/mL) of trypsinogen 
(24 kDa), cytochrome C (12 kDa) and insulin (5.8 kDa) as standard 
proteins (Sigma-Aldrich) using a polynomial equation, as suggested by 
the manufacturer. All spectra were processed and analyzed using the 
MassLynx 4.0 software. The instrument source voltage was set to 12 kV. 
The pulse and detector voltages were optimized at 1999 V and 5200 V, 
respectively. Measurements were performed in the mass range m/z 3000-
30000 with a suppression mass gate set to m/z 1000 and an extraction 
delay of 600 ns. Data were recorded by accumulating and averaging at 
least 10 spectra randomly acquired over the well surface. After averaging, 
spectra were processed for peak smoothing. To observe at best the 
rhGKN1●Aβ(1-40) complex, we performed scouting experiments by 
changing the amount and type of matrices and the protein/peptide ratio. 
The complex was observed at best using sinapinic acid (solution 10 
mg/mL in ethanol/NH4HCO3 at 1:1 molar ratio, v/v) as the ionizing 
matrix and at 1:1 molar ratio of rhGKN1:Aβ. Optimized spectra were 
therefore acquired on a solution containing 10 pmol/µL rhGKN1 in 5 mM 
NaP and 10 pmol/µL Aβ in 1% DMSO. All spectra were acquired by 
spotting 1 μL of matrix solution on the target plate dried at room 
temperature. Then, protein/peptide samples (1 μL) were applied on top of 
the matrix crystal layer and dried again. A second matrix layer (1 μL), 
was formed on top of the sample layer preparation resulting in a matrix-
sample-matrix sandwich. Spectra were collected after complete solvent 
evaporation. MALDI-MS experiments were also performed separately on 
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10 pmol/µL rhGKN1 and Aβ peptide solutions, under the same 
conditions. 
 
2.6 Size-Exclusion Chromatography (SEC) 
SEC was performed on an AKTA Purifier System using a Superdex 75  
prepacked gel filtration column for high-resolution (GE Healthcare). The 
column was equilibrated and eluted at a flow rate 0.5 mL/min with 100 
mM NaCl and 50 mM NaP pH 7.0 and the absorbance at 280 nm was 
recorded. The elution volumes of the following standard proteins were 
used for column calibration: bovine serum albumin (BSA) (66 kDa), 
carbonic anhydrase (30 kDa) and cytochrome C (12 kDa). rhGKN1 (30 
µg in 10 mM NaP pH 7.0 and 150 mM NaCl 10% (v/v) DMSO) was first 
loaded into the column alone and then the various fractions (tetramer, 
dimer and monomer) were incubated in the presence of Aβ(1-40) in a 1:3 
molar ratio. Before loading, all the samples were incubated at 37 °C for 1 
hour. 
 
2.7 Surface Plasmon Resonance analysis 
Surface plasmon resonance (SPR) measurements were performed using a 
Biacore 3000 instrument (GE Healthcare). Aβ peptide (1-40) was 
covalently immobilized to the dextran matrix of a CM5 sensor chip via 
the primary amine groups (amine coupling kit; GE Healthcare). The 
carboxymethylated dextran surface was activated by the injection of a       
mixture of 0.2 M N-ethyl-N’-(diethylamino-propyl)carbodiimide and 0.05 
M N-hydroxysuccinimide (EDC/NHS chemistry) according to the 
manufacturer's instructions (23). The immobilization of ligand was 
efficiently performed at 15.0 µg/mL in 10 mM sodium acetate buffer 
(NaOAc) pH 4.0 containing 2.5% DMSO deriving from the peptide stock 
solution. The remaining N-hydroxysuccinimide esters were blocked by 
injection of 1 M ethanolamine hydrochloride (O-AEA) pH 8.5. Reference 
channel was prepared and used as control blank. All immobilization steps 
were performed at a flow rate of  5 μl/min using 10 mM HEPES, 150 mM 
NaCl, 3 mM EDTA, 0.005% P20 (HBS-EP, GE Healthcare) (pH 7.4) as 
running buffer. rhGKN1 was injected at different concentrations ranging 
from 7.5 μM to 130 μM. After each injection the surface was regenerated 
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with pulses of a solution of 10 mM sodium hydroxide (NaOH). The 
activity of the immobilized peptide was not affected by the regeneration 
conditions employed and the chip were reusable to achieve two 
independent sets of binding experiments. Analyses were performed at 25 
°C at a flow rate of 20 μl/min in HBS-EP buffer (GE Healthcare). In all 
binding experiments, association phases ran for 180 seconds and 
dissociation phases for 300 seconds.  Non-specific binding from the 
reference channel was subtracted from the working channels using the 
BIAevaluation analysis package (version 4.1, GE Healthcare). Data were 
fitted using the software GraphPad Prism 5, versus 5.0 (GraphPad 
Software). 
 
2.8 Cell culture and transfection 
Human gastric adenocarcinoma cell line (AGS) was grown in DMEM-
F12 (Dulbecco’s modified Eagle medium-Cambrex) supplemented with 
heat inactivated fetal bovine serum (FBS), 1% penicillin/streptomycin and 
1% L-glutamine at 37 °C in a 5% CO2 atmosphere. Cells (250000/well) 
were seeded into six well plates 24 hours prior to transfection in DMEM-
F12 antibiotics free (2 ml) and then transfected with 4 µg of vector 
(pcDNA 3.1 or pcDNA-GKN1) by using lipofectamine 2000 (LF2000) 
according to the manufacturer’s instructions (Invitrogen). The efficiency 
of transfection of gastric cancer cells with GKN1 was always evaluated 
by a parallel transfection using EGFP vector as control. In general, after 
transfection, the average value of the ratio green fluorescent cells/total 
number of cells was of 0.5±0.1. As control, untransfected cells were 
treated with 2 μM DAPT or only DMSO for 24 hours. 
 
2.9 Cytosolic extracts and Western blot analysis 
Cells were trypsinized, washed twice in cold phosphate buffered saline 
(PBS) and resuspended in 20-40 µl of lysis buffer (50 mM Tris–HCl pH 
7.4, 1% NP-40, 0.25% NaDC, 150 mM NaCl, 1 mg/ml aprotinin, 
leupeptin, pepstatin, 1 mM Na3VO4, 1mM NaF) for 30 minutes on ice and 
centrifuged at 14000 rpm for 20 minutes at 4°C. Protein concentration 
was determined by a modified Bradford method (24), using the Bio-Rad 
(Milan, Italy) protein assay and compared with BSA standard curve. 
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Equal amounts of cytosolic proteins (70 µg) were separated by SDS–
PAGE, electrotransferred to PVDF membrane and reacted with the 
specific antibody anti-Amyloid Precursor Protein (Sigma-Aldrich). 
Immunoblots were visualized using HRP-conjugated secondary 
antibodies and ECL Western blot detection kit (GE Healthcare). All films 
were analyzed by using Image J software. 
 
2.10 Pull-Down 
Pull-down of GKN1 was performed using Ni-NTA agarose (Qiagen). Cell 
extracts (500 µg) were incubated with equal amounts of pre-equilibrated 
resin (200 µl slurry/1 mg protein extract) over night at 4 °C. After the 
incubation, the resin was washed two times (centrifugation for 2 minutes 
at 2000 rpm and 4 °C) in 50 mM NaH2PO4, 300 mM NaCl and 10 mM 
imidazole to reduce nonspecific bound proteins, resuspended in 10 µl of 
2× Laemmli loading buffer, heated to 95 °C for 5 minutes and subjected 
to Western blot analysis as described above.  
 
2.11 mRNA isolation and qRT-PCR  
Total RNA was extracted from normal and cancer human tissue samples 
using TRIzol reagent solution (Invitrogen) according to the 
manufacturer’s protocol. cDNA was synthesized using the reverse 
transcription kit from Roche Molecular Systems (Roche) according to the 
manufacturer's protocol. GKN1 cDNA was amplified by qRT-PCR using 
forward and reverse primers 5′-CTTTCTAGCTCCTGCCCTAGC-3′ and 
5′-TGGTTGCAGCAAAGCCATTT-3′, respectively, according to 
standard procedures (Applied Biosystems). qRT-PCR was performed 
with the SYBR Green PCR MasterMix (Applied Biosystems) under the 
following conditions: 10 minutes at 95 °C, followed by 40 cycles (15 
seconds at 95 °C and 1 minute at 60 °C). Each reaction was performed in 
duplicate. We used the 2–ΔΔCT method to calculate the relative expression 
levels (25). 
 
2.12 Chromatin Immunoprecipitation assay 
Samples from normal and cancer human tissues were processed for 
chromatin immunoprecipitation assay. Cellular sospension was collected 
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by centrifugation at 2000 rpm at 4 °C for 10 minutes and then 
resuspended in 6× volume of cell lysis buffer (5 mM PIPES pH 8.0, 85 
mM KCl, 0.5% NP-40) plus PMSF (1 mM) and trypsin inhibitor (10 μg/ 
mL) as protease inhibitors. Cells were then incubated on ice for 15 
minutes and lysed using a dounce several times. Nuclei were collected at 
5000 rpm at 4 °C for 10 minutes and the pellet was resuspend in 5× 
volume of nuclei lysis buffer (50 mM TrisHCl pH 8.1, 10 mM EDTA, 1% 
SDS) plus the same protease inhibitors as the cell lysis buffer. The 
solution was incubate on ice for 20 minutes and subsequently freezed and 
thawed in liquid nitrogen 2 times to aid in nuclear lysis. After 
centrifugation at 5000 rpm at 4 °C for 10 minutes, the supernatant 
obtained was the chromatin. Samples were subjected to IP with the 
following specific antibodies against istonic modification anti-tri methyl 
K9-Histone3 (Abcam) and against the specific histone methyltransferase 
anti-SUV39H1 (Millipore). For qPCR, 3 μl of 150 μl IP DNA were 
amplified with a set of three pairs of primers covering a promoter region 
from -427bp to +91bp around the transcriptional start site on GKN1 gene. 
 
Promoter Region: 
                A         Forward: 5′-GGGGTAGGTTTGGTGGGAGTTGC-3′  
                    Reverse: 5′-ATCACAGCTGAAAAGCCACGTGTA-3′ 
                B         Forward: 5′-CGCCCACAGCTTTGACTGGGT-3′  
                    Reverse: 5′-TGCCATGAGCCAGTGTACCAGGA-3′ 
                C         Forward: 5′-TCCTGGTACACTGGCTCATGGCA-3′  
                    Reverse: 5′-AGCAGTGGACAGAGGAGTAGGCA-3′ 
 
GAPDH promoter amplicon was used as a negative control in all 
experiments (data not shown). IgGs were used as nonspecific controls, 
and input DNA values were used to normalize the values from 
quantitative ChIP samples.  
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RESULTS 
 
Part A. Interaction between recombinant human GKN1 and the 
amyloid peptide Aβ(1-40) 
 
3.1 rhGKN1 prevents the aggregation and fibril formation of Aβ(1-
40) 
SDS-PAGE was first utilized to study the effects of rhGKN1 on Aβ 
aggregation. Aβ(1-40) peptide was incubated with rhGKN1 and with the 
control protein chicken cystatin at 10:1 molar ratios. As reported in Fig. 
3A, at zero time incubation, the amounts peptide was quite similar in all 
samples whereas, compared to the peptide alone (left panel) or the peptide 
incubated in presence of chicken cystatin (middle panel), no reduction in 
the amount of Aβ was observed up to 25 hours when the peptide was 
incubated in the presence of rhGKN1 (right panel). Similar results were 
also observed after 7 days incubation (Fig. 3B). In fact, a drastic reduction 
of the amount of Aβ was observed for the samples corresponding to Aβ 
alone (left panel) or the sample co-incubated with chicken cystatin 
(middle panel). The sample containing rhGKN1 (right panel) showed, 
instead, almost similar amounts of soluble Aβ as observed at time zero 
incubation. These results suggest that rhGKN1 was able to prevent Aβ 
aggregation. 
The ability of rhGKN1 to prevent Aβ peptide aggregation was also 
analyzed by Thioflavin T binding experiments. As reported in Fig. 4, 
compared to Aβ peptide alone, rhGKN1 was able to prevent the 
polymerization of Aβ(1-40). 
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Figure 3. rhGKN1 prevents aggregation of Aβ(1-40). (A) 17.3 μM Aβ(1-40) 
incubated from 0 up to 24 hours alone in the absence or in the presence of 1.7 μM 
chicken cystatin (middle panel) or 1.7 μM rhGKN1 (right panel) and  (B) 17.3 μM Aβ(1-
40) incubated from 0 up to 7 days in the absence or in the presence of 1.7 μM chicken 
cystatin (middle panel) or 1.7 μM rhGKN1 (right panel). All incubations were performed 
in 10 mM sodium phosphate buffer (pH 7.0) and 150 mM sodium chloride with 10% 
(v/v) DMSO. 
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Figure 4. rhGKN1 inhibits Aβ(1-40) polymerization. Thioflavin T fluorescence 
binding was assessed at different times of incubation (0-4 hours) of 8.5 μM Aβ(1-40) 
alone or in the presence of 1.7 μM rhGKN1. A sample of 1.7 μM rhGKN1 alone was 
also included. Experiments were performed in duplicate with similar results. 
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3.2 rhGKN1 forms a complex with Aβ(1-40) 
The putative interaction of rhGKN1 with β-amyloid peptide was 
investigated by MALDI-MS under non-denaturing conditions (Farmer 
TB, 1998). To observe at best the rhGKN1●Aβ(1-40) complex, MS 
analyses were performed under different experimental conditions by 
changing the amount and type of matrices and the protein/peptide ratio. 
The optimized conditions for detecting the complex included the use of 
sinapinic acid (solution 10 mg/mL in ethanol/NH4HCO3 at 1:1 molar 
ratio, v/v) as ionizing matrix and a 1:1 molar ratio of rhGKN1:Aβ, as 
described in the Methods section. The MS spectrum of Aβ(1-40) is shown 
in Fig. 5A. Only a signal corresponding to the peptide (m/z 4331.0, 
theoretical average [M+H]+= 4330.8 Da) was detected. Similarly, when 
rhGKN1 was analysed in isolation (Fig. 5B), a peak corresponding to the 
monomeric protein was expectedly observed at m/z 19406.0 (theoretical 
average [M+H]+= 19408.6  Da). By analysing the mixture of rhGKN1 
and Aβ (Fig. 5C), an ion peak at m/z 23734.7 was clearly revealed, 
attesting the occurrence of a 1:1 rhGKN1●Aβ(1-40) complex (theoretical 
average [M+H]+= 23738.45  Da). 
Size-Exclusion Chromatography (SEC) was then employed to better 
characterize the interaction between rhGKN1 and β-amyloid peptide (Fig. 
6). The 280 nm absorbance elution profile for rhGKN1 fractions 
(tetramer, dimer and monomer), individually incubated in the absence 
(black line) and in the presence (red line) of Aβ(1-40), showed the 
tendence of the latter to dissociate the aggregated forms of the protein and 
to promote the monomeric form. It must be observed that the 
chromatographic profile did not show the presence of a peak 
corresponding to the rhGKN1●Aβ complex probably because, due to the 
low affinity, it dissociated during the chromatographic separation. 
The possible interaction between rhGKN1 and Aβ(1-40) was also 
analysed using a bioinformatic approach such as that of generating a 
docking model. To this purpose, the pdb files corresponding to GKN1 
BRICHOS domain and Aβ(1-40) were submitted at GRAMM-X Protein-
Protein Docking Web Server v.1.2.0 (26, 27). The pdb GKN1 BRICHOS 
domain file was generated at Swiss-Model Server (28) using as template 
the recent crystal structure of pro-SP-C BRICHOS domain, Protein Data 
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Bank code 2yad (16) whereas the 2LFM.pdb file corresponded to the 
NMR structure of Aβ(1-40) (29). As illustrated in Figure 7, the docking 
model obtained supports the formation of a possible complex between 
GKN1 BRICHOS domain and Aβ(1-40). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. rhGKN1 forms a complex with Aβ(1-40). (A) MALDI-TOF spectra of Aβ; 
(B) rhGKN1 and (C) rhGKN1 in the presence of Aβ. A magnification of the ion peak at 
m/z 23734.7 corresponding to the 1:1 rhGKN1●Aβ(1-40) complex (theoretical average 
[M+H]+= 23738.45  Da) is reported in C. 
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Figure 6. Size-Exclusion Chromatography analysis. Elution profiles at 280nm from 
the size-exclusion chromatography on Superdex 75 column obtained for rhGKN1 
fractions in the absence (black line) and in the presence (red line) of Aβ(1-40).  
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Figure 7. Imitation of a 3D model of the GKN1 (BRICHOS domain)●Aβ(1-40) 
complex. The representation was obtained from the molecular docking pdb file 
(Model_1-1.pdb) using PyMol software (DeLano Scientific LLC). 
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3.3 rhGKN1/Aβ interaction is specific but characterized by a low 
affinity 
To probe the specificity of the interaction between rhGKN1 and Aβ and 
to determine their affinity constant in a quantitative manner, surface  
plasmon resonance analyses were performed. The β-amyloid peptide was 
successfully immobilized on the destran matrix of a CM5 sensor chip at 
about 1400 RU density. Fig. 8A depicts the binding sensorgrams of 
freshly prepared rhGKN1 in HBS buffer injected at different 
concentrations ranging from 7.5 to 130 µM on the immobilized β-amyloid 
surface. The specificity of binding was verified achieving saturation at the 
highest tested concentration of 130 µM. A dissociation constant (KD) of 
3.4±0.7*10-5 was extrapolated by data fitting of a plot of RUmax values 
from each binding determination against protein concentration, using a 
non-linear regression analysis (Fig. 8B). Chiken cystatin, used as negative 
control, did not show any reliable and measurable binding response to Aβ 
when tested at 60 µM (Fig. 8C), further confirming the specificity of 
binding. 
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Figure 8. Surface plasmon resonance analysis. (A) Sensorgrams of the binding of 
rhGKN1 to Aβ(1-40) immobilized on CM5 sensor chip, tested at the concentrations 
between 7.5 to 130 mM. Experiments were carried out at a 25 °C, at a constant flow rate 
of 20 µL/min using HBS as running buffer. (B) Plot of RUmax from each single binding 
experiment versus concentration (µM). By data fitting using a nonlinear regression 
algorithm (GraphPad Prism 4) a KD= 3.4+0.7*10-5 M was calculated. (C) Sensorgram of 
the no-binding of chicken cystatin tested at the concentration of 60 mM to Aβ(1-40) 
immobilized on the surface of a CM5 sensor chip. 
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3.4 GKN1 binds amyloid precursor protein and inhibits γ-secretase 
activity 
Since rhGKN1 was able to interact with Aβ peptide, it was tested if the 
protein was able to interact with amyloid precursor protein (APP) in a 
gastric cancer cell line. To this purpose, AGS cells were transfected with 
GKN1 cDNA His-tagged (pcDNA-GKN1) and after pull-down assay 
with Ni-NTA agarose were analysed by Western blot using anti-APP 
antibody. As reported in Fig. 9 (upper panel) transfected AGS cell 
specifically pulled-down for His-tagged GKN1 showed the presence of 
APP, thus indicating its interaction with GKN1. This result led to the 
hipothesis that GKN1 might participate in the processing of the Aβ 
precursor. Therefore, transfected AGS cells were analysed with specific 
antibody anti-APP able to recognize the APP processing products. As 
control, it was used a γ-secretase inhibitor (DAPT) able to highlight the 
internmediate processing products (CTFs). As shown in Fig. 9 (lower 
panel) there was an increase of the CTFs accumulation that was 
proportional to the time of transfection. This results strongly indicated 
that GKN1 exerts an inhibitory activity toward γ-secretase.  
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Figure 9. GKN1 and amyloid precursor protein. (Upper panel) Transfected AGS 
cells extracts were pull-down with Ni-NTA agarose and washed with 10 mM imidazole. 
The Ni-NTA resin was directly loaded on SDS-PAGE and analyzed by Western blot 
using anti-APP antibody. Lane 1, transfected AGS cells; lane 2, untransfected AGS 
cells; lane 3, Ni-NTA alone. (Lower panel) Inhibition of γ-secretase activity in APP 
processing in AGS cells. (A) CTFs levels in control samples in the presence or absence 
of DAPT. (B) CTFs levels in AGS cells transfected with pcDNA3.1 (lane 1) and AGS 
cells after transfection with pcDNA-GKN1 at 12, 24 and 48 hours (lane 2, 3 and 4, 
respectively). Histogram represents the percentage of band intensity with respect to 
GAPDH levels. Each measurement and Western blot was carried out in triplicate. Error 
bars indicate the maximum deviation from the mean value of two independent 
experiments. 
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Part B. Histone modification associated to GKN1 gene silencing 
 
3.5 GKN1 down-regulation in gastric cancer is associated with 
H3K9triMe on GKN1 promoter 
To investigate the possible causes of GKN1 gene inactivation, it was 
examined a group of three different samples derived from biopsies of 
normal and tumor human gastric tissue. Tissue extracts were first 
analysed to determine the GKN1 mRNA level by qRT-PCR and Western 
blot (Fig. 10 A and B). Subsequently, chromatin immunoprecipitation 
assays (ChIP) were performed for the repressive histone modification 
H3K9triMe. For this preliminary study, it was considered a promoter 
region of the human GKN1 gene covering from -427bp to +91bp around 
the transcriptional start site. The results obtained showed that in the tumor 
tissue of the three subjects examined there is a very significant presence 
of this histone modification on GKN1 gene promoter, contrary to what 
observed in the normal tissue of the same (Fig. 11 sample 1, 2 and 3).  
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Figure 10. GKN1 expression in human gastric tissue. (A) GKN1 cDNA levels by 
qRT-PCR. Error bars indicate the maximum deviation from the mean value of two 
independent experiments. Asterisks indicate statistically significant differences at a p < 
0.001 level. (B) GKN1 protein levels by Western blot and relative band intensity 
evaluation with respect to α-tubulin levels. Each measurement and Western blot was 
carried out in triplicate. Error bars indicate the maximum deviation from the mean value 
of two independent experiments. 
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Figure 11. H3K9triMe levels on human GKN1 gene promoter. Results of ChIP 
assays on human gastric tissue samples. Percent input was calculated as 2ΔCt × 100, 
where ΔCt is the difference between CtInput and CtIP. NoIP (IgGs control) have been 
subtracted from IP. All quantitative ChIP data were derived from at least three 
independent experiments, and for each experiment, qPCR was performed in triplicate. 
Error bars indicate the maximum deviation from the mean value of two independent 
experiments. Asterisks indicate statistically significant differences at a p < 0.001 level.  
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3.6 High levels of H3K9triMe were associated with recruitment 
and/or activation of the specific HMT SUV39H1 on GKN1 promoter 
At this stage it was important to clarify who operates this modification on 
GKN1 promoter. Literature data indicate that this histone modification is 
made by a specific histone methyltransferase, called SUV39H1 that 
trimethylates 'Lys-9' of histone H3 using monomethylated H3 'Lys-9' as 
substrate. So the next step was to verify by ChIP assays the presence of 
this enzyme on gene promoter in human gastric tissues. These preliminary 
findings show an increase in the binding of SUV39H1 on the same 
regions analyzed for histone modification (Fig. 12).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. SUV39H1 levels on human GKN1 gene promoter. Results of ChIP assays 
on human gastric tissue samples. Percent input was calculated as 2ΔCt × 100, where ΔCt 
is the difference between CtInput and CtIP. NoIP (IgGs control) have been subtracted from 
IP. All quantitative ChIP data were derived from at least three independent experiments, 
and for each experiment, qPCR was performed in triplicate. Error bars indicate the 
maximum deviation from the mean value of two independent experiments. Asterisks 
indicate statistically significant differences at a p < 0.001 level. 
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DISCUSSION/CONCLUSIONS 
Gastrokine 1 (GKN1) is a stomach-specific protein important for 
maintaining the physiological function of the gastric mucosa, being 
involved in the replenishment of the surface lumen epithelial cell layer and 
in maintaining mucosal integrity. Individuals with a lower expression of 
the protein have an increased risk of developing gastric diseases. The 
protein, in fact, is downregulated in H. pylori-infected gastric tissues and a 
loss of the protein expression is detected in gastric cancer tissues and 
precancerous lesions (13-15). So it is thus clear that the expression of 
GKN1 decreased throughout the progressive stages of neoplastic 
transformation, from gastritis to intestinal metaplasia, and it plays an 
important role in the process of formation and development of gastric 
cancer. It has also been demonstrated that GKN1 expression induces 
apoptosis in gastric cancer cells (10). This finding was also confirmed by 
the ability of recombinant human GKN1 (rhGKN1) to exert a higher 
antiproliferative effect on gastric cancer cells (AGS) compared to normal 
human embryonic kidney cells (HEK 293) and non-gastric cancer cells 
(H1355) (11). The higher sensitivity of AGS cells to GKN1 exposure was 
likely linked to the role played by GKN1 in maintaining gastric mucosal 
integrity and to its function as a gastric tumor suppressor. 
For these reasons, it becomes very important to identify and 
characterize the molecular mechanisms that involve GKN1 to better 
identify its biological role in gastric tissue and in the process of 
carcinogenesis. To this aim, this thesis was initially aimed at verifying 
whether the GKN1 possess a role of chaperone against amyloidogenic 
peptides. The results obtained in the first part of the study showed the 
ability of rhGKN1 in reducing the fibrils aggregation of β-amyloid peptide 
(1-40), one of the main components of senile plaques in Alzheimer' s 
disease that is also ubiquitary. Further investigations have confirmed the 
formation of a GKN1● Aβ complex characterised by a KD of 34 µM. 
These data highlighted a chaperon-like property of GKN1 (or its 
BRICHOS domain) in binding and preventing the formation of 
amyloidogenic b-sheet folding. In prevention or treatment of amyloid 
diseases, it appears essential to identify new chaperones with some level of 
specificity for Aβ and/or with its precursor protein APP and to understand 
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at which stage of APP processing and/or Aβ aggregation these specific 
chaperones might interfere. To give a biological interpretation of the 
results observed in vitro, it was hypothesized that GKN1 could interct with 
APP in gastric cells. This hypothesis was experimentally confirmed by 
pull-down assay in gastric cancer cell lines transfected with GKN1. 
Moreover, it was also explored the intervention of GKN1 in the processing 
of the Aβ precursor. What interestingly emerged was an activity of GKN1 
as inhibitor of proteolytic γ-cleveage.  Literature indicates that γ-secretase 
inhibitors (GSIs) are emerging as a new class of anticancer agents for the 
treatment of solid and hematological malignancies, but little is known 
about their effects on gastric cancer. GSIs are the indirect inhibitors of 
Notch, a single-pass transmembrane receptor protein whose pathway is 
overexpressed in several tumors (30). Thus it is probable that the apoptotic 
activity of GKN1 against gastric cancer cells was correlated indirectly 
with the inhibition of  γ-secretase observed. Further investigations are 
necessary to clarify this aspect.  
Regarding the mechanism by which GKN1 gene is down-regulated 
in gastric cancer, this remains still an open question so the second section 
of my work was focused to clarify the causes of GKN1 gene inactivation 
and to determine if epigenetic mechanisms could be involved in this 
process. The data obtained showed for the first time a possible epigenetic 
mechanism of histone modifications that could lead to disregulate GKN1 
gene transcription in gastric cancer. In fact, we have observed the massive 
presence of the repressive histone modification H3K9triMe and the 
recruitment of the specific histone methyltrasnferase SUV39H1 on the 
GKN1 gene promoter in human tumor tissues with respect to normal 
tissues. These results are much more relevant and reliable if considered 
that it was obtained in vivo on human gastric tissue samples. These 
findings represent the first step in the characterization of the epigenetic 
machinery that leads to gene silencing in gastric cancer and there will be 
further studies aimed at this purpose. Next goal will be to identify the 
specific transcription factor that is able to bind GKN1 promoter and to 
recruit a corepressor complex including SUV39H1 and/or other histone 
modifier enzymes in gastric cancer tissues. Understanding whether GKN1 
gene inactivation can play a key role in the switch from normal gastric 
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tissue to gastric carcinogenesis may be important to identify the early 
stages of the disease and to make efficient screening of risk patients. 
Under this aspect, to understand the molecular epigenetic mechanisms that 
could lead to gene silencing and to determine whether this event might be 
involved in the development and progression of gastric cancer would 
provide an essential starting point for the development of new therapeutic 
strategies based on epigenetic targets for alternatives gene.  
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